OrbiMed

Last updated

OrbiMed Advisors LLC
FormerlyMehta & Isaly
Company type Private
Industry Investment management
Founded1998;26 years ago (1998)
FounderSamuel Isaly
Michael Sheffery
Arvind Desai
Headquarters Citigroup Center, New York City, New York, U.S.
Products Public equity
Private equity
Venture capital
Private credit
AUM US$21 billion (March 31, 2021)
Number of employees
100 [1]
Website www.orbimed.com
Footnotes /references
[2]

OrbiMed (OrbiMed Advisors) is an American investment firm based in New York City, United States. It is focused on making public and private investments in the Healthcare and Biotechnology industries. OrbiMed is considered one of the world's largest dedicated healthcare investment firms. [3]

Contents

Background

In 1989, S.G Warburg pharmaceutical analysts Viren Mehta and Samuel Isaly founded Mehta & Isaly, a money-management and research firm. This was the predecessor firm to OrbiMed. [3] [4] [5] [6] [7] The firm made its first venture capital investment in 1993. [7]

In 1998, Mehta & Isaly split up into two entities, with Mehta forming Mehta Partners and Isaly forming OrbiMed Advisors. [3] [5] [8]

In 2007, OrbiMed expanded into Asia, opening offices in Shanghai and Mumbai. In 2010, the firm expanded into the Middle East, opening an office in Herzliya, Israel. [9]

In December 2017, Isaly stepped down from his role as managing partner of OrbiMed due to allegations of sexual harassment raised by former female employees. [4] [7] [10] [11]

Notable investments

Related Research Articles

<span class="mw-page-title-main">Charles River Laboratories</span> American biotechnology and pharmaceutical corporation

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Cinven Limited is a global private equity firm founded in 1977, with offices in nine international locations in Guernsey, London, New York, Paris, Frankfurt, Milan, Luxembourg, Madrid, and Hong Kong that acquires Europe and United States based corporations, and emerging market firms that fit with their core businesses, and necessitate a minimum equity investment of €100 million or more. As of 2023, it has €39 billion in assets under management.

Venture philanthropy is a type of impact investment that takes concepts and techniques from venture capital finance and business management and applies them to achieving philanthropic goals. The term was first used in 1969 by John D. Rockefeller III to describe an imaginative and risk-taking approach to philanthropy that may be undertaken by charitable organizations.

Fosun International Limited is a Chinese multinational conglomerate holding company. Founded in 1992 by Guo Guangchang and four others, the company is headquartered in Shanghai and was incorporated in Hong Kong in 2004. Its Co-CEOs are Chen Qiyu and Xu Xiaoliang. Wang Qunbin joined Guo Guangchang as co-chairman in early 2020. The company is located in 16 countries and is one of the largest privately owned conglomerates in China. It was ranked 371st on the Forbes Global 2000 ranking in 2020.

<span class="mw-page-title-main">Francisco Partners</span> American private equity firm

Francisco Partners Management, L.P., doing business as Francisco Partners, is an American private equity firm focused exclusively on investments in technology and technology-enabled services businesses. It was founded in August 1999 and based in San Francisco with offices in London and New York City.

Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The two firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.

Corporate venture capital (CVC) is the investment of corporate funds directly in external startup companies. CVC is defined by the Business Dictionary as the "practice where a large firm takes an equity stake in a small but innovative or specialist firm, to which it may also provide management and marketing expertise; the objective is to gain a specific competitive advantage." Examples of CVCs include GV and Intel Capital.

Onward Technologies is an Indian multinational software technology outsourcing company specializing in digital and ER&D services, transportation & mobility, industrial equipment, heavy machinery, and healthcare & Med-Tech industries.

<span class="mw-page-title-main">Ohio bioscience sector</span> Significant economic sector in the state

The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.

Solomon Partners, previously known as PJ Solomon and/or Peter J. Solomon Company, is an independently operated American investment bank and financial services company headquartered in New York City. Solomon Partners advises on mergers, acquisitions, divestitures, restructurings, recapitalizations, SPACs and capital markets.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $450 million in March 2022, after raising its Opportunity Fund II totaling $300 million in September 2021.

<span class="mw-page-title-main">Radius Ventures</span> American venture capital firm

Radius Ventures is a venture capital firm located in New York that invests in expansion-stage health and life sciences companies. Founded in 1997 by Jordan S. Davis and Daniel C. Lubin, Radius has raised in excess of $200 million in three funds and has invested in over 40 companies since inception. Radius invests in leading-edge, growth equity and expansion-stage health and life sciences companies.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.

American Well Corporation, doing business as Amwell, is a telemedicine company based in Boston, Massachusetts, that connects patients with doctors over secure video. Amwell sells its platform as a subscription service to healthcare providers to put their medical professionals online and its proprietary software development kits, APIs, and system integrations enable clients to embed telehealth into existing workflows utilized by providers and patients.

BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 (Plenity) for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.

Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised five funds: Foresite Capital Fund I, II, III, IV and V.

PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

References

  1. ↑ "Sponsors for the 13th ELSF Forum". SachsForum.
  2. ↑ "Form ADV as of 3/30/2021" (PDF). SEC.gov.
  3. 1 2 3 "Orbimed drug portfolio balances prognosis with prevention". Institutional Investor. September 22, 2009. Retrieved July 15, 2023.
  4. 1 2 "ObriMed Advisors founder to step down, be replaced by management committee". Pensions & Investments. December 8, 2017. Retrieved May 22, 2021.
  5. 1 2 "Mehta & Isaly Investment Firm Splits". The New York Times. January 6, 1998. ISSN   0362-4331 . Retrieved May 22, 2021.
  6. ↑ Kreutzer, Laura. "OrbiMed Seeks $4.75 Billion for Fresh Slate of Healthcare-Focused Funds". WSJ. Retrieved July 15, 2023.
  7. 1 2 3 McElhaney, Alicia (January 3, 2018). "Their Hedge Fund's Founder Was Accused of Sexual Harassment. Here's What They Did Next". Institutional Investor. Retrieved July 15, 2023.
  8. ↑ "OrbiMed Advisors". FierceBiotech. October 8, 2014. Retrieved May 22, 2021.
  9. ↑ "ORBIMED ADVISORS LLC Profile and Investing Strategy - GuruFocus.com". www.gurufocus.com. Retrieved May 22, 2021.
  10. ↑ "Isaly steps down from hedge fund giant OrbiMed after harassment claims". STAT. December 8, 2017. Retrieved May 22, 2021.
  11. ↑ Norton, Leslie P. "OrbiMed's Sam Isaly Steps Down Amid Accusations of Sexual Misconduct". www.barrons.com. Retrieved May 22, 2021.
  12. ↑ "AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform". www.abcellera.com. Retrieved May 22, 2021.
  13. ↑ Baum, Stephanie (November 1, 2013). "OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014". MedCity News. Retrieved May 22, 2021.
  14. ↑ "Ambit Biosciences Completes $30 Million Series D-2 Financing". www.businesswire.com. June 10, 2011. Retrieved May 22, 2021.
  15. ↑ "BRIEF-Orbimed Advisors acquired 480,000 common shares of Cynapsus Therapeutics". Reuters. July 7, 2016. Retrieved May 22, 2021.
  16. ↑ "DFine raises $36.2M to repair spine fractures". VentureBeat. July 16, 2010. Retrieved May 22, 2021.
  17. ↑ Says, Anon (January 3, 2008). "Xconomy: Obesity Startup Gelesis Gobbles Up $16M in Financing". Xconomy. Retrieved May 22, 2021.
  18. ↑ "Intercept Pharmaceuticals Closes $30 Million Series C Financing". www.prnewswire.com (Press release). Retrieved May 22, 2021.
  19. ↑ "Natera Completes $54.6 Million Financing to Support Expansion, Continued Global Rollout of Non-Invasive Prenatal Test Panorama™ | Natera, Inc". investor.natera.com. Retrieved May 22, 2021.
  20. ↑ Hay, Timothy (August 28, 2012). "OmniGuide Raises $35M in Debt From OrbiMed Advisors". Wall Street Journal. ISSN   0099-9660 . Retrieved May 22, 2021.
  21. ↑ "TigerText Closes on $50 Million in Financing to Accelerate Growth; Launches TigerText Anywhere Initiative". TigerConnect. Retrieved May 22, 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.